US Stock MarketDetailed Quotes
APLS Apellis Pharmaceuticals
- 27.980
- +0.720+2.64%
Close Nov 1 16:00 ET
- 27.980
- 0.0000.00%
Post 20:02 ET
3.41BMarket Cap-10286P/E (TTM)
28.105High27.110Low3.25MVolume27.310Open27.260Pre Close90.62MTurnover3.97%Turnover RatioLossP/E (Static)121.77MShares73.80052wk High12.89P/B2.29BFloat Cap26.28052wk Low--Dividend TTM81.89MShs Float94.750Historical High--Div YieldTTM3.65%Amplitude11.450Historical Low27.871Avg Price1Lot Size
About Apellis Pharmaceuticals Company
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Company Profile
SymbolAPLS
Company NameApellis Pharmaceuticals
Listing DateNov 9, 2017
Issue Price14.00
Founded2009
CEODr. Cedric Francois, M.D.
MarketNASDAQ
Employees706
Fiscal Year Ends12-31
Address100 5th Avenue
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02451-8703
Phone1-617-977-5700
Websitehttp://www.apellis.com
Company Executives
- Name
- Position
- Salary
- Dr. Cedric Francois, M.D.
- Director, Chief Executive Officer and President
- 10.37M
- Karen Lewis
- Chief People Officer
- --
- Timothy E. Sullivan
- Chief Financial Officer and Treasurer
- 3.74M
- Adam J. Townsend
- Chief Operating Officer
- 3.71M
- Nur Nicholson
- Chief Technical Operations Officer
- --
- Dr. Caroline Baumal, M.D.
- Chief Medical Officer
- 4.43M
- Mark Jeffrey DeLong
- Chief Business and Strategy Officer
- --
- Dr. Jeffrey Eisele, PhD
- Chief Development Officer
- --
- Pascal Deschatelets, PhD
- Chief Scientific Officer
- --
- James George Chopas
- Vice President, Corporate Controller and Chief Accounting Officer
- --
- Dr. Gerald L. Chan, Sc.D.
- Chairman of the Board
- 504.08K
- Stephanie Monaghan O’Brien
- Independent Director
- 488.46K
- A. Sinclair Dunlop
- Independent Director
- 480.96K
- Paul Fonteyne, M.S.
- Independent Director
- 489.08K
- Alec Machiels
- Independent Director
- 495.96K
- David Watson
- General Counsel
- 4.89M
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
